The announcement by President Donald Trump’s administration of the results of a probe into pharmaceutical imports and new sector-specific tariffs are likely “weeks away,” which would be later than initially promised, reported Reuters, citing official and industry sources. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Trump, pharma industry discuss increasing medicine spending abroad, Reuters says
- Trump Weekly: President says raising tariffs on India ‘substantially’
- Trump says separate tariff announcements coming for semi chips, pharmaceuticals
- Trump posts letters calling on drug company CEOs to lower prices
- Press Secretary says Trump sent letters today to pharmaceutical companies